

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *					2. Issuer Name <b>and</b> Ticker or Trading Symbol							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Lee Howard					Amphastar Pharmaceuticals, Inc. [ AMPH								X Director 10% Owner				
(Last)	) (Firs	t) (Mi	iddle)	3. I	Date	of Earlie	est Trans	action	1 (MM	I/DD/YYY	(Y)		Officer (giv	e title below	() Oth	er (specify b	pelow)
C/O AMPHA PHARMAC 6TH STREE	EUTICA	ALS, INC	C., 11570	0			6/:	5/20	23								
	(Str	eet)		4. I	f Ar	nendmer	it, Date C	rigin	al Fi	led (MM/	/DD/	/YYYY)	6. Individual o	or Joint/G	roup Filing	(Check Appl	icable Line)
RANCHO C	CUCAMO	ONGA,,	CA 917	30									X Form filed by		ting Person One Reporting P	'erson	
(0	City) (St	ate) (Zip		tha	Che t is i	eck this b	to satisfy	icate the a	that a	a transac native de	efen	nse cond	nade pursuant to	10b5-1(c)			ten plan
1. Title of Security (Instr. 3)			Trans. Date			3. Trans. Co (Instr. 8)	ode	or Di	Securities Acquired (Disposed of (D) str. 3, 4 and 5)		Fo	Amount of Securit ollowing Reported nstr. 3 and 4)	ities Beneficially Owned Transaction(s)		6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
						Code	v	Amount (A)			Price				or Indirect (I) (Instr. 4)	(Instr. 4)	
Common Stock				6/5/2023			A		2716	( <u>1</u> ) A		\$0.00	1	45655		D	
	Tal	ole II - Der	ivative S	ecurities l	Ben	eficially	Owned (	e.g.,	puts,	, calls, v	var	rants, o	ptions, conver	tible secu	ırities)		
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deeme Execution Date, if any	Code	5. Number Derivative Acquired (Appropriate of Control o		e Securities (A) or of (D)	and E	6. Date Exercisable and Expiration Date		Se D (In	. Title and A ecurities U Perivative S Instr. 3 and	nderlying Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exerci	eisable	Expiration Date	n Ti	ïtle	Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (right to buy)	\$46.01	6/5/2023		A		7016			(2).	6/5/2031		Common Stock	7016	\$0	7016	D	

### **Explanation of Responses:**

- (1) The reported shares are represented by restricted stock units, or RSUs, all of which vest on June 5, 2024.
- (2) All of the shares subject to the option vest on June 5, 2024.

### **Reporting Owners**

Reporting Owner Name / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Lee Howard						
C/O AMPHASTAR PHARMACEUTICALS, INC.	X					
11570 6TH STREET	11					
RANCHO CUCAMONGA,, CA 91730						

#### **Signatures**

/s/ Eva Wen, by power of attorney	6/7/2023
**Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.